US ▾
IOIOVA

Iovance Biotherapeutics (IOVA) Q2 FY26 earnings call: guidance and Q&A

Earnings call· Jun 2026 (Q2 FY26)· Aug 6, 2026

Source: earnings call transcript

Executive summary

Iovance Biotherapeutics Q2 FY26 — Record Revenue and Margin, Pipeline Advancement

Iovance Biotherapeutics delivered a robust second quarter, driven by record revenue and expanding gross margins, primarily from strong Ampagni demand. The company is advancing its clinical pipeline with key regulatory designations and trial progress, while also managing operating expenses effectively. Management is reviewing its full-year revenue guidance, anticipating an upward revision in the third quarter, reflecting confidence in continued commercial momentum and operational discipline.

Highlights

5

  • Record total revenue of $99.3 million, up 66% year-over-year and 39% sequentially.

  • Ampagni revenue reached a new high of approximately $91 million, exceeding guidance.

  • Gross margin increased to an all-time high of 56%, up from 41% in Q1 FY26.

  • R&D expenses decreased for the fourth consecutive quarter to $59 million, reflecting efficiency gains.

  • FDA granted Fast Track designation for SAR201 in two advanced soft tissue sarcomas.

Concerns

2

  • Perlucan revenue slightly down to $9 million from $11 million in the prior quarter due to wholesaler inventory timing.

  • Full-year 2026 total revenue guidance of $350-$370 million is under review, with an update planned for Q3.

Guidance & targets

CategoryTargetConfidence
Full-year 2026 Total Revenue
$350M-$370M
high materiality
Medium
Perlucan as % of Total Revenue
in line with 2025
medium materiality
High
Perlucan as % of Total Revenue (rest of year)
approximately 16%
medium materiality
High
Cash Runway
into the second half of 2028
high materiality
High
Authorized Treatment Centers (ATCs)
at least 110
medium materiality
High
Lung 202 sBLA Submission
supplemental biologic splicense application
high materiality
High
IOB5001 (G1-TIL-1) Program Updates
more updates
low materiality
High

Segment performance

SegmentRevenueYoYQoQMargin
Ampagni
Ampagni sales reached a new high, driven by increased physician awareness, ATC network expansion, and deepening clinical evidence, including real-world data showing >50% response rates in patients with two or fewer lines of therapy.
Exceeded Q2 guidance range of $79M-$81MKey growth driverCommercial momentum carrying into Q3
$91M68%51%—
Perlucan
Perlucan sales were slightly impacted by wholesaler inventory timing but demand remains strong, with wholesalers now ordering in line with Ampagni demand. It is a high-margin product.
Slightly down from prior quarter due to timing of wholesaler inventory stockingExpected to be ~16% of total revenue for rest of yearExpected to be in line with 2025 as a percentage of total revenue for FY26
$9M—down from $11M—
International (Ampagni)
Iovance is expanding Ampagni into new international markets, with initial ATCs opening for private pay patients while working towards public reimbursement. Australia has the highest rate of melanoma globally.
Approved in CanadaApproved in AustraliaRegulatory approvals pending in UK and SwitzerlandWorking towards resubmission in EU
————

Risks & headwinds

Wholesaler inventory timing for Perlucan Q2 FY26

Perlucan revenue slightly down from $11 million to $9 million in Q2 FY26

Mitigation:Wholesalers have sold through previous stocking inventory and are now ordering in line with Ampagni demand.

Competitive landscape for TIL therapies Near to medium term

RepliMune's agent potentially entering the market; Obsidian going public as a TIL competitor.

Mitigation:Iovance views RepliMune as competitive with TVEC, not Ampagni, due to Ampagni's superior profile and real-world experience. Iovance highlights its significant lead, infrastructure, and experience over other TIL competitors like Obsidian.

What to watch in Q3 FY26

Full-year 2026 Total Revenue Guidance Update

Q3 FY26
Current $350M-$370M (under review)
Target Revised guidance (expected higher)

Why it matters

A revised guidance will reflect management's updated confidence in commercial momentum and operational performance for the full year.

Once we fully assess increasing growth trends, we expect to provide an update to our full year guidance during the third quarter.

Find out whether IOVA delivers this. Inve re-checks your case every morning.

Q&A highlights

Was Q2 revenue purely organic demand or timing? Clarify Lung 202 data release: complete enrollment then follow-up on all, or majority?

Q2 demand was organic, driven by increased awareness, ATC expansion, and clinical data. Lung 202 will complete enrollment before material update, but not necessarily wait for every patient's full follow-up.

“Just to add to Dan, just to be very clear, Andrew, there's not a timing issue or anything. This is organic demand for the product. It's looking very good right now based on all the factors that Dan described and more that we really do expect that demand is going to continue to increase significantly for Ampagby throughout the coming quarters.”

asked by Andrew Sy · answered by Frederick Vogt

2 min read 5 chapters

Detailed narrative

Commercial Momentum and Market Expansion

Iovance reported record Q2 FY26 revenue and margin, driven by strong demand for Ampagni. The company is expanding its Authorized Treatment Center (ATC) network, with community ATCs now representing one-third of the network and expected to grow significantly. This expansion, coupled with increasing physician awareness and deepening clinical evidence, is broadening access and driving earlier adoption of Ampagni.

Pipeline Advancement in Solid Tumors

The company is making significant progress across its clinical pipeline. Enrollment is nearly complete in the pivotal cohorts of the Lung 202 trial for non-squamous non-small cell lung cancer, with an sBLA targeted for 2027. The Saratoga trial for SAR201 in soft tissue sarcomas received Fast Track designation from the FDA, following promising pilot study data showing a 50% objective response rate.

Next-Generation TIL Therapies and Biomarker Strategy

Iovance is investing in next-generation programs, including the G1-TIL-1 trial using IOB5001, an IL-12 tethered TIL therapy, targeting prevalent solid tumors. The company is also leveraging a histology-based biomarker strategy, which produced striking early Phase 2 data in metastatic serous endometrial cancer (N201 trial) with a 40% confirmed objective response rate, leading to engagement with the FDA for an expedited approval pathway.

Operational Efficiency and Financial Discipline

The company demonstrated strong operational leverage, with gross margin reaching an all-time high of 56% due to higher volume, cost optimization, and maturing internal manufacturing efficiencies. Research and development expenses decreased for the fourth consecutive quarter, while selling, general, and administrative expenses remained flat, contributing to a cash runway extending into the second half of 2028.

International Expansion and Regulatory Progress

Iovance continues to expand its global footprint, having secured approvals for Ampagni in Canada and Australia. Regulatory approvals are pending in the United Kingdom and Switzerland, and the company is working towards resubmission in the European Union, aiming to serve a globally addressable patient population of over 30,000 annually for previously treated melanoma.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.